Real World Assessment of Effects of Beta-blockers on Patients With Acute Coronary

Chinese Academy of Medical Sciences, Fuwai Hospital1 site in 1 country2,200 target enrollmentAugust 31, 2018

ConditionsAcute Coronary Syndrome

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Acute Coronary Syndrome
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
Enrollment: 2200
Locations: 1
Primary Endpoint: Major adverse cardiovascular and cerebrovascular events (MACCE)
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The study is aimed to optimized the dose-adjusted regimen of beta-blockers in patients with acute coronary syndrome by investigating therapeutic and curative results of target doses Beta-blockers using the dose-adjusted pathway of beta-blockers.

Registry

clinicaltrials.gov

Start Date

August 31, 2018

End Date

July 31, 2022

Last Updated

7 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital

Responsible Party

Principal Investigator

Yi-Da Tang

Professor

Chinese Academy of Medical Sciences, Fuwai Hospital

Eligibility Criteria

Inclusion Criteria

•Age ≥ 18 years
•Patients diagnosed as acute coronary syndromes including acute ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevated acute coronary syndrome (NSTE-ACS)
•Patients or whose legal representatives signed written informed consent form

Exclusion Criteria

•Patients should been excluded if they meet any of the following exclusion criteria:
•Patients with contraindications to the application of beta blockers, including: 1) cardiogenic shock or heart failure (Killip grade \> II level);2) sick sinus syndrome; 3) II degree atrioventricular block;4) unstable decompensation of cardiac failure (pulmonary edema, hypotension or low perfusion); 5) symptomatic hypotension or bradycardia (heart rate\<50 beats/min, blood pressure\<90/60mmHg); 6) contraindications to beta blockers or allergy to any ingredient of beta blocker; 7) active asthma should be treated by inhalation preparation treatment
•Pregnant or lactating women
•Patients without signed written informed consent
•Patients who was considered by the researcher inappropriate to participate in this study (for example, patients with a higher risk of cardiogenic shock, etc.)

Outcomes

Primary Outcomes

Major adverse cardiovascular and cerebrovascular events (MACCE)

Time Frame: Within 1 year after surgery

MACCE were defined as a composite of all-cause death, myocardial infarction (MI), unplanned target vessel revascularization (TVR), stent thrombosis (ST) and stroke.